Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma

Abstract

Objective. To evaluate the efficacy of low dose apatinib plus chemotherapy on advanced gastric carcinoma. Methods. Eligible 50 patients with advanced gastric carcinoma admitted to the hospital from January 2019 to March 2020 were enrolled, and they were assigned into the control group ( $n=25$ , chemotherapy) and observation group (apatinib plus chemotherapy). Changes of CEA, CA72-4, and VEGF levels were measured, and the efficacy of the two groups was evaluated by referring to KPS and RECIST. Results. Significant reduction was observed in CEA, CA72-4, and VEGF in both groups, and the treatment in the observation group resulted in a greater reduction (all $P<0.05$ ). The observation group obtained significantly higher KPS scores of compared with the control group ( $P<0.05$ ). In addition, the treatment in the observation group led to a better control rate in relative to the control group according to RECIST the score ( $P<0.05$ ). Conclusion. The combination of low dose apatinib and chemotherapy might be a promising option for advanced gastric cancer and it merits clinical application.